Penny Stocks
EOSE: Revenue Growth Faces the Gross-Margin Test Ahead of November 5 Earnings
Eos’s preliminary sales growth supports the manufacturing-ramp story, but deeply negative gross margins remain the key financial test.
Read the storyPenny Stocks
STORIES WITH TASTE
Penny StocksOCGN: Clinical Milestones and Cash Runway Put the Pipeline Ahead of the Earnings Headline
Ocugen’s November 4 update advances the clinical story, but its narrower net loss includes a large derivative-liability gain.
Penny StocksHPAI: A 300-Unit AI Deployment Target Meets a Late-Filing Warning
Helport’s autonomous-AI expansion offers a growth narrative, while its late-filing notice warns of falling revenue and a net loss.
Penny StocksXMAX: A $30 Million Buyback Authorization Meets a Weaker Sales Picture
XMax authorized purchases below $5.50 per share, but the program is conditional and preliminary results show declining sales and a loss.
Penny StocksCMTG: Loan Resolutions and Lower Debt Put a Troubled Mortgage Portfolio in Focus
Claros resolved $409.5 million of loans and reduced financing, but losses and troubled-property exposure remain central to the story.
Penny StocksSTIM: Revenue Growth and Positive Adjusted EBITDA Give the Rally Substance
Neuronetics reported stronger third-quarter sales and positive adjusted EBITDA, while a GAAP loss and cash needs keep the turnaround unfinished.
Penny StocksIMNN: ThermoDox Deal Gives a Written-Off Asset a New Path
IMUNON’s proposed ThermoDox sale offers contingent future value while management focuses on its Phase 3 ovarian-cancer program.
Penny StocksKTTA: Pasithea Approaches Its October 23 Cancer-Data Presentation
An upcoming ESMO presentation gives Pasithea a defined clinical event as its shares rebound. The actual data will matter more than anticipation.
Penny StocksSHFS: Nasdaq Gives Safe Harbor More Time as Shares Rebound
A new compliance deadline gives Safe Harbor breathing room. Restoring its bid price and strengthening the business remain separate challenges.
Penny StocksNUAI: New Era’s AI Data-Center Plan Faces the Tenant Test
Power arrangements and credit support advance New Era’s infrastructure plan. Signed leases and project economics are the next commercial tests.
Penny StocksPDSB: A New Board as PDS Biotech Prepares Its Next Cancer-Trial Push
A board refresh gives PDS Biotechnology a timely business milestone. Clinical planning, financing and eventual patient evidence remain the investment tests.
Penny StocksDFSC: From Army Demonstrations to Commercial Orders—DEFSEC’s Next Test
DEFSEC’s corporate update puts product readiness and sales execution in focus. The key question is whether demonstrations and production become profitable customer orders.